We analyzed entry data from 163 adult hemoglobin SS and Sb 0 thalassemia patients enrolled in the prospective Sickle Cell Pulmonary Hypertension Screening Study and stratified their ECHO-determined tricuspid regurgitant jet velocity (TRV) and serum creatinine concentration according to three systemic blood pressure categories. TRV was 2.5 m/sec in 27% of the patients with systolic blood pressure (SBP) < 120 mmHg and diastolic blood pressure (DBP) <70 mmHg, in 37% with SBP 120-139 mmHg or DBP 70-89 mmHg, and in 93% with SBP 140 mmHg or DBP 90 mmHg or higher (P < 0.0005 for trend). Serum creatinine concentration was 1.0 mg/dL or higher in 7% of patients with SBP < 120 mmHg and DBP < 70 mmHg, in 17% with SBP 120-139 mmHg or DBP 70-89 mmHg and 50% with SBP 140 mmHg or DBP 90 mmHg or higher (P < 0.0005 for trend). Over 2 years of follow-up, there were trends for more frequent progression to elevated TRV (P 5 0.073) or creatinine (P 5 0.037) values according to the higher systemic blood pressure categories. Our findings suggest that systemic SBP 120-139 mmHg or DBP 70-89 mmHg defines a category of relative systemic hypertension in patients with sickle cell disease that is associated with increased risk for pulmonary hypertension and renal dysfunction. Whether antihypertensive and/or nitric oxide donor therapy in sickle cell disease patients with relative hypertension prevents these and other complications should be determined by clinical trials. Am. J. Hematol. 83:15-18, 2008. 
Introduction
A number of studies document that SCD is associated with lower systemic blood pressures than controls [1] [2] [3] [4] [5] [6] [7] and with a lower prevalence of systemic hypertension [1, 2, 5, 7] . Potential mechanisms for the lower blood pressures in SCD patients include obstruction of the vasa recta in the kidney and repeated ischemia to the renal medulla, resulting in a distal renal tubular concentrating defect and hyposthenuria [8] , lower body mass index in patients with SCD [4] , and lower arterial stiffness [9] .
The finding that patients with sickle cell disease have low blood pressure seems to counter recent pathophysiological studies suggesting that these patients develop endothelial dysfunction and systemic vasculopathy associated with reductions in NO bioavailablity [10] [11] [12] [13] [14] [15] [16] [17] . However, blood pressures in SCD are higher than in thalassemia patients with a similar degree of anemia [2] , and there is an association between cerebrovascular accident and higher blood pressures in SCD, even in a range of systolic and diastolic pressures that would be considered normal by conventional standards [2, 3] . These studies raise the possibility that the normal range for blood pressure in patients with SCD should be lower than in healthy controls.
A recent report [7] confirmed that hemoglobin SS patients have lower systolic blood pressures (SBPs) than age-matched African-American controls, but that those with heterozygous sickling hemoglobinopathies (SC, SbThal) have SBPs identical to age-matched African-American controls from NHANES III data.
In our recently published study of adult sickle cell disease patients [6] , we found significantly higher systemic systolic and mean systemic blood pressures in patients with pulmonary arterial hypertension (PAH), as defined by tricuspid regurgitant jet velocity (TRV) 2.5 m/sec, than in those without PAH. This finding is consistent with the possibility that similar pathophysiologic pathways underlie both systemic and PAH in SCD. We found that the measures of renal function, BUN, and creatinine were significantly elevated in SCD patients with PAH as well.
Elevated systemic blood pressures also contribute to left ventricular diastolic dysfunction, which has been shown to be an independent predictor of death in SCD patients [18] . SCD patients who had systolic BP > 75th percentile (131 mmHg) had significantly increased left ventricular mass by echocardiography and Doppler evidence of diastolic dysfunction. A good correlation between the E/A ratio and the serum creatinine level was found suggesting that these were both end-organ effects of relative systemic hypertension. Accordingly, the purpose of the present study was to determine if relative systemic hypertension (i.e., SBP 120-139 mmHg or DBP 70-89 mmHg) is associated with complications and adverse outcomes in SCD.
Results
One hundred and sixty-three patients with hemoglobin SS (N 5 158) or Sb 0 (N 5 5) thalassemia were evaluated with echocardiogram, serum creatinine determination, or both, and 86 underwent repeat evaluations a median of 24 months later (interquartile range of 23-27 months). The baseline characteristics of the patients are summarized in Table I . Forty-six percent of the patients had systemic blood pressures of <120 mmHg systolic and <70 mmHg diastolic (classified as normal), 44% had SBP of 120-139 mmHg or DBP of 70-89 mmHg (classified as relative hypertension) and 10% had SBP 140 mmHg or DBP 90 mmHg (classified as hypertension). None of the patients with SBP < 120 mmHg and DBP < 70 mmHg were on hemodialysis, but 3% in the relative systemic hypertension category and 13% with blood pressure 140 mmHg systolic or 90 mmHg diastolic were dialysis dependent. Median values for TRV, creatinine, and blood urea nitrogen increased significantly according to higher systemic blood pressure categories. There was a trend to higher lactate dehydrogenase levels with higher blood pressure categories (P 5 0.077). In a Spearman correlation of SBP and lactate dehydrogenase, a significant positive relationship was found (n 5 141, R 5 0.172, P 5 0.041). There were no significant differences in baseline blood pressure, TRV, or creatinine between patients who did and did not have a 2-year follow-up (P > 0.2).
Elevated TRV values according to systemic blood pressure categories
The prevalence of TRV 2.5 m/sec was 27% with SBP < 120 mmHg and DBP < 70 mmHg, 37% with SBP 120-139 mmHg or DBP 70-89 mmHg, and 93% with SBP 140 mmHg or DBP 90 mmHg ( Fig. 1) . Of the 69 patients with initial TRV < 3.0 m/sec who were followed-up 2 years later, TRV increased from <2.5 m/sec to 2.5 m/ sec or from 2.5-2.9 m/sec to 3.0 m/sec in 13 (19%). The progression rate was 10% with normal blood pressure, 25% with relative hypertension, and 33% with elevated blood pressure (Fig. 2) .
Elevated serum creatinine concentration according to systemic blood pressure categories
The prevalence of serum creatinine 1.0 mg/dL was 7% with SBP < 120 mmHg and DBP < 70 mmHg, 17% with SBP 120-139 mmHg or DBP 70-89 mmHg, and 50.0% with SBP 140 mmHg or DBP 90 mmHg (Fig. 3) . Of the 63 patients with initial serum creatinine concentration 1.4 mg/dL who were followed-up 2 years later, serum creatinine increased from <1.0 mg/dL to 1.0 mg/dL or from 1.0-1.4 mg/dL to 1.5 mg/dL in 6 (9.5%). The progression rate was 3% with normal blood pressure, 12% with relative hypertension, and 29% with elevated blood pressure (Fig. 4 ).
Progression to hypertension over 2 years of follow-up
At the 2-year follow-up evaluation, hypertension was observed in none of 19 patients who initially had SBP < 120 mmHg and DBP < 70 mmHg and in 2 of 19 (16%) of those with relative systemic hypertension at initial evaluation.
Discussion
In the emerging paradigm of SCD vasculopathy, increased risk for PAH and systemic hypertension, renal dysfunction, proteinuria, stroke, and early death may be related to the degree of hemolysis, nitric oxide scavenging, and resultant damage to the vasculature [6, 19, [20] [21] [22] [23] . Other risk factors identified that are associated with PAH and vasculopathy include markers of iron overload, left ventricular diastolic dysfunction, asplenia, and cholestatic hepatic dysfunction [6, 18] . In this study, we postulated that, similar to patients with diabetes mellitus and renal failure [24] , systemic SBP 120-139 mmHg or DBP 70-89 mmHg may represent relative hypertension in patients with hemoglobin SS and Sb 0 thalassemia and identify patients at increased risk for PAH and renal dysfunction. Consistent with our hypothesis, we observed increasing prevalences of elevated TRV and creatinine values with the three progressively higher systemic blood pressure categories. We also observed trends to more rapid progression to elevated TRV or creatinine over 2 years of follow-up according to these increasing blood pressure categories.
Given the high mortality in SCD patients with PAH [6, 25, 26] and the high progression rate we observed over 2 years, it is important to find ways to prevent the progression to PAH. Similarly, given the high mortality in patients with end stage renal disease and the progression to elevated serum creatinine concentration over 2 years, it is important to find ways to prevent progression of renal dysfunction. It is possible that treating relative systemic hypertension in patients with hemoglobin SS and Sb 0 thalassemia may inhibit progression to PAH, the advance of renal disease and other vascular complications. In the general population, control of systemic hypertension is essential in preventing cardiovascular complications. It is possible that in SCD control of relative systemic hypertension may be required as well. Even mild increases in pulmonary artery pressure are poorly tolerated in SCD patients [6, 25, 26] and the same may apply to systemic blood pressures.
Limitations to this study include that only half of the patients enrolled participated in the 2-year follow-up and that the present report on relative systemic hypertension is based on a retrospective analysis.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) describes an independent, continuous risk between BP and risk of cardiovascular disease and recognizes the importance of this relationship by introducing a new classification called prehypertension [24] . Patients in this category (SBP 130-39 or DBP 80-89) are felt to be at significantly increased risk of progressing to hypertension and JNC 7 identifies six compelling conditions for which antihypertensive therapy should be instituted. These conditions include heart failure, postmyocardial infarction, high coronary disease risk, diabetes mellitus, chronic kidney disease, and recurrent stroke prevention. Our present study adds to the growing body of evidence associating end-organ effects in the heart, lung, and kidneys with relative systemic hypertension in the SCD population. Thus, SCD may be an additional condition for which antihypertensive therapy should be started at or below the prehypertension level. Clinical trials are needed to guide initiation of therapy and treatment goals in the SCD population.
Methods
The patient population consisted of 163 adults with hemoglobin SS or Sb 0 thalassemia who participated in the Sickle Cell Pulmonary Hypertension Screening Study and who had values recorded for SBP and also values for TRV by echocardiogram, serum creatinine concentration, or both. All patients gave written informed consent and were enrolled between February 2001 and March 2005. Details of the clinical and echocardiographic methods (and study results for most of these patients) were reported previously [6] . For 86 patients in this cohort, follow-up echocardiograms, serum creatinine concentrations, and/or systemic blood pressures were determined 2 years after their initial enrollment. The present report represents a retrospective analysis, although all of the data were collected prospectively.
For the present study, patients were categorized as having normal systemic blood pressure (<120 mmHg systolic and <70 mmHg diastolic), relative hypertension (SBP 120-139 mmHg or DBP 70-89 mmHg), or hypertension (SBP 140 mmHg or DBP 90 mmHg) based on the baseline blood pressures determined at study entry. Patients with systemic blood pressures > 140 mm/Hg systolic or >90 mmHg diastolic at enrollment were treated with anti-hypertensive agents, but those with lower systemic blood pressures were not.
Elevated TRV was taken to be 2.5 m/sec. The relationship of pulmonary blood pressure determined by right heart catheterization with TRV determined by echocardiography has been documented in several studies [6, 27] . For example, in a study of 41 patients with SCD, TRV correlated with mean pulmonary artery pressure (R 5 0.76, P <0.001), pulmonary vascular resistance (R 5 0.55, P < 0.001), maximal oxygen uptake (R 5 20.43, P 5 0.011), and the 6 min walk test (R 5 20.55, P < 0.001) [27] . Elevated serum creatinine concentration was taken to be 1.0 mg/dL. We chose this serum creatinine value as indicative of early renal involvement because among the cohort of hemoglobin SS patients < 40 years of age in the large CSSCD cohort, the 75th percentiles for serum creatinine values were at or below 1.0 mg/dL [28] . The mean ± SD body mass index (BMI) in patients with an elevated creatinine was 21.8 ± 4.4 kg/m 2 while the BMI in those with a normal creatinine was 23.6 ± 6.1 kg/m 2 (P 5 0.130).
Continuous variables were compared according to blood pressure category with the Kruskal-Wallis test and categorical variables with Cochran's linear trend test.
